Former FDA Officials Sound Alarm: Visible Changes May Be “Tip of the Iceberg”

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER director spoke to analysts about potential implications for drug review timelines and agency morale.